Alembic Pharmaceuticals: Alembic Pharmaceuticals Limited receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL
Alembic Pharmaceuticals (APLLTD) filed a disclosure titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL". The company is valued at about ₹14,941 crore.
What happened
Alembic Pharmaceuticals (APLLTD) filed a disclosure with the exchanges on 27 October 2026 at 03:29 PM titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL".
Company snapshot
Alembic Pharmaceuticals is a small-cap company in the Healthcare sector, with a market value of about ₹14,941 crore.
The stock last traded at ₹760.1, against a 52-week range of ₹635.8–₹998 (23.8% below the high).
Before this filing the shares had moved −9.5% over the month and −4.7% over three months. Average daily turnover over the last 20 sessions was about ₹15.24 crore.
Promoters held 69.87% at the end of Q1 FY27, up 0.13% points from the previous quarter. Foreign institutions owned 4.18% and domestic institutions 15.94%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,711 | 154.4 | 7.85 |
| Q2 FY26 | 1,910 | 184.7 | 9.4 |
| Q3 FY26 | 1,876 | 133 | 6.76 |
| Q4 FY26 | 1,848 | 201.5 | 10.31 |
| Q1 FY27 | 2,150 | 173.1 | 8.8 |
What history shows
This is not the company's first approval disclosure: BCEIE has at least 12 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 1.6% on average the next trading day and was up 3.2% on average after five days (9 filings with price data).
Across 109 similar disclosures by other Healthcare companies, shares moved +0.3% on average the next day and +0.8% over five days; 50% of them rose the next day.
Market-wide, 1,520 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 16 Sept 2026 | Update on USFDA inspection conducted during 3rd March, 2025 to 7th… | +2.5% | +3.0% |
| 11 Sept 2026 | Successful completion of unannounced USFDA onsite inspection at… | −0.7% | +3.6% |
| 7 Sept 2026 | Approval | +2.2% | +3.2% |
| 28 Jul 2026 | Approval | −0.3% | −0.6% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Alembic Pharmaceuticals Limited Estimates – NSE:APLLTD
- Alembic Pharmaceuticals Gets USFDA Final Approval For Ear Infection Drug
- Alembic Pharmaceuticals Receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Ear Suspension
- Alembic Pharmaceuticals Receives USFDA Approval for Ear
- Alembic Pharmaceuticals secures USFDA approval for Valganciclovir oral solution
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.